Investigational drug · Phase 3
Xaluritamig
Also called: AMG 509
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Castration-resistant Prostate Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
9
Any phase or sponsor naming "Xaluritamig"
First trial start
2024
Dec 9, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Xaluritamig", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Castration-resistant Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Xaluritamig" as an intervention, largest first.
- A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07213674 · 750 participants (planned) · Start Nov 28, 2025 · Primary completion Jan 7, 2030
Drug: Xaluritamig; Abiraterone acetate and 2 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Goodyear, Arizona; Tucson, Arizona; Duarte, California · 159 sites in all
- Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)Pivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT06691984 · 707 participants · Start Dec 9, 2024 · Primary completion Jan 2, 2029
Drug: Xaluritamig; Abiraterone and 2 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Birmingham, Alabama; Duarte, California; Fullerton, California · 164 sites in all
- Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT04221542 · 505 participants (planned) · Start Mar 4, 2020 · Primary completion Jul 28, 2030
Drug: AMG 509; Abiraterone and 1 more · For: Prostate Cancer
Sites: Duarte, California; Fullerton, California; San Francisco, California · 54 sites in all
- Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate CancerActive, not recruiting
AmgenAmgen (AMGN)
NCT07140900 · 60 participants (planned) · Start Oct 7, 2025 · Primary completion Oct 27, 2027
Drug: Xaluritamig; Darolutamide and 1 more · For: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Sites: San Francisco, California; Boston, Massachusetts; Minneapolis, Minnesota · 16 sites in all
AmgenAmgen (AMGN)
NCT07297979 · 50 participants (planned) · Start Apr 8, 2026 · Primary completion May 26, 2030
Drug: Xaluritamig · For: Ewing Sarcoma
Sites: Los Angeles, California; Baltimore, Maryland; Boston, Massachusetts · 13 sites in all
- Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate CancerActive, not recruiting
AmgenAmgen (AMGN)
NCT06555796 · 50 participants · Start Sep 23, 2024 · Primary completion Mar 13, 2027
Drug: Xaluritamig · For: Prostate Cancer; High-risk Biochemical Recurrence; High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer and 1 more
Sites: Minneapolis, Minnesota; New York, New York; Chapel Hill, North Carolina · 11 sites in all
AmgenAmgen (AMGN)
NCT07493512 · 40 participants (planned) · Start Apr 28, 2026 · Primary completion Jul 30, 2030
Drug: Xaluritamig · For: Metastatic Castration-resistant Prostate Cancer (mCRPC)
Sites: Denver, Colorado; Durham, North Carolina; Cincinnati, Ohio · 14 sites in all
AmgenAmgen (AMGN)
NCT06613100 · 40 participants (planned) · Start Nov 25, 2024 · Primary completion Feb 17, 2027
Drug: Xaluritamig; GnRH Antagonist · For: Prostate Cancer
Sites: San Francisco, California; St Louis, Missouri; Columbus, Ohio · 9 sites in all
- LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide TetraxetanNot yet recruiting
Thomas Jefferson UniversityAcademic, hospital or other
NCT07737925 · 30 participants (planned) · Start Oct 2026 · Primary completion Oct 2030
Drug: Xaluritamig · For: Prostate Cancer; Metastatic Castrate Resistant Prostate Cancer
Newest research
PubMed records naming it or its code names, newest first.
- T-Cell-Engaging Bispecific Therapies and Ocular Inflammation Emerging Phenotypes, Immunologic Mechanisms, and Clinical Management.
Alhadlag A · Ocul Immunol Inflamm 2026
- STEAP1-targeted strategies in advanced prostate cancer: a review on therapeutic and diagnostic implications.
Heo JY, Sheng M, Khalaf D, et al. · Prostate Cancer Prostatic Dis 2026
- Immunotherapeutic strategies for castration-resistant prostate cancer: A systematic review of mechanisms, clinical advances and emerging approaches.
Xu Z, Xia Z, Li J, et al. · Mol Biol Rep 2026
- Precision-Engineered CD3 T-Cell Engagers for Solid Tumours: Conditional Activation, Microenvironment Modulation, and Clinical Translation.
Zeyaullah M, AlShahrani AM, Khan MS, et al. · Cancers (Basel) 2026
- Novel Immunotherapeutic Strategies for Castration-Resistant Prostate Cancer: Mechanisms and Clinical Advances.
Xia X, Xia Z, Yu L · Curr Issues Mol Biol 2026
- Orbital Inflammatory Syndrome Associated with Bispecific T-Cell Engager Therapy: Case and Literature Review.
Eisen JN, Arat YO, Maeng MM · Ophthalmic Plast Reconstr Surg 2026
Also in development for Metastatic Castration-resistant Prostate Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- ONC-392Gotistobart, BNT316Phase 35 trials
OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
- 177Lu-NYM032Phase 32 trials
Norroy Bioscience Co., LTD · Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- BMS-986365Phase 31 trial
Bristol Myers Squibb · Metastatic Castration-resistant Prostate Cancer
- DeutenzalutamidePhase 31 trial
AstraZeneca · Metastatic Castration-resistant Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Amgen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.